The Function and Regulation of Platelet P2Y12 Receptor

被引:0
|
作者
Xiaohua Li
Guoxing Zhang
Xia Cao
机构
[1] The First Hospital of Jilin University,Department of Infectious Diseases
[2] Jilin University,Department of Pharmacology, School of Pharmacy
[3] ICU,undefined
[4] Ji Lin Tumor Hospital,undefined
来源
关键词
P2Y12; Platelet; P2Y12 antagonists; Inflammation; Regulation;
D O I
暂无
中图分类号
学科分类号
摘要
In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely used in cardiovascular diseases worldwide in recent decades due to their potent antiplatelet and antithrombotic effects. Meanwhile, the role of P2Y12 in inflammatory diseases has also been extensively studied. Relatively, there are few studies on the regulation of P2Y12. This review first summarizes the various roles of P2Y12 in the process of platelet activation, as well as downstream effects and signaling pathways; then introduces the effects of P2Y12 in inflammatory diseases such as sepsis, atherosclerosis, cancer, autoimmune diseases, and asthma; and finally reviews the current researches on P2Y12 regulation.
引用
收藏
页码:199 / 216
页数:17
相关论文
共 50 条
  • [31] The Effectiveness of P2Y12 Receptor Antagonist Therapy is Strongly Determined by Endothelial Mediators of Platelet Function
    Knowles, Rebecca B.
    Chan, Melissa V.
    Armstrong, Paul C.
    Shih, Chih-Chin
    Hayman, Melissa A.
    Vojnovic, Ivana
    Tucker, Arthur T.
    Timmis, Adam D.
    Warner, Timothy D.
    CIRCULATION, 2014, 130
  • [32] Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests
    Valgimigli, Marco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 : S8 - S15
  • [33] Platelet P2Y12 Receptor InhibitionAn Update on Clinical Drug Development
    David Vivas
    Dominick J. Angiolillo
    American Journal of Cardiovascular Drugs, 2010, 10 : 217 - 226
  • [34] A MULTI-DISCIPLINARY APPROACH TO PLATELET P2Y12 RECEPTOR RESEARCH
    Cunningham, M.
    Mundell, S.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 5 - 6
  • [35] Pleiotropic Effects of Platelet P2Y12 Receptor Inhibitors: Fact or Fiction?
    Moulias, Athanasios
    Xanthopoulou, Ioanna
    Alexopoulos, Dimitrios
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (28) : 4597 - 4604
  • [36] Platelet P2Y12 Receptor Inhibition An Update on Clinical Drug Development
    Vivas, David
    Angiolillo, Dominick J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (04) : 217 - 226
  • [37] Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists
    Tang, Jie
    Li, Mu-Peng
    Zhou, Hong-Hao
    Chen, Xiao-Ping
    CURRENT VASCULAR PHARMACOLOGY, 2015, 13 (05) : 566 - 577
  • [38] Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation
    Douglass, James G.
    deCamp, J. Bryan
    Fulcher, Emilee H.
    Jones, William
    Mahanty, Sanjoy
    Morgan, Anna
    Smirnov, Dima
    Boyer, Jose L.
    Watson, Paul S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 2167 - 2171
  • [39] Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis
    Conley, PB
    Delaney, SM
    CURRENT OPINION IN HEMATOLOGY, 2003, 10 (05) : 333 - 338
  • [40] The promise of effective P2Y12 platelet receptor pretreatment: Not crushed yet
    Chatterjee, Arka
    Hillegass, William B.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 91 (02) : 251 - 252